# Treatment of Psychosis and Agitation in Alzheimer's Disease

> **NCT02129348** · PHASE2 · COMPLETED · sponsor: **New York State Psychiatric Institute** · enrollment: 77 (actual)

## Conditions studied

- Alzheimer's Disease
- Psychosis
- Agitation

## Interventions

- **DRUG:** Lithium
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02129348
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2020-01
- **Final completion:** 2020-01
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2024-05-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02129348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02129348, "Treatment of Psychosis and Agitation in Alzheimer's Disease". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02129348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*